Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

Marie Skłodowska-Curie Action · Running

DuoLipo-TNP DuoLipo-TNP: Dual-Responsive Liposome Platform for Selective Delivery of Triphosphate Nucleotide Prodrugs in Triple-Negative Breast Cancer

Coordinator
Cardiff University, United Kingdom
Runs
30 April 2027 to 29 April 2029
Status
Running
EU funding
€260k
Total cost
—
Partners
2 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101281416

What the project is doing

In the project's own words, from its summary on CORDIS.

Breast cancer is the most frequently diagnosed cancer in women worldwide and a leading cause of cancer mortality in Europe, with triple-negative breast cancer (TNBC) representing the most aggressive and therapy-resistant subtype. Driven by tumor heterogeneity, poor vascularization, and a hostile microenvironment, TNBC urgently requires new therapeutic strategies, an unmet clinical need directly aligned with the EU Mission on Cancer.

DuoLipo-TNP seeks to address these challenges by developing dual-responsive liposomal nanocarriers for the selective delivery of γ-masked triphosphate nucleotide prodrugs (TNPs). The platform combines tumor-penetrating iRGD peptides for αvβ3/αvβ5 integrin-mediated vascular targeting with lipid components responsive to hypoxia and acidic pH, two hallmark features of TNBC. This dual-triggered strategy enables site-specific release of active antimetabolites, bypasses kinase-dependent activation, and minimizes systemic toxicity.

The project applies a multidisciplinary approach spanning prodrug synthesis, advanced liposomal formulation and characterization, and comprehensive pharmacological validation in 2D and 3D TNBC models, including patient-derived spheroids. Ultimately, DuoLipo-TNP aims to establish a platform for intratumoral delivery of nucleotide analogues, advancing precision nanomedicine and contributing to the EU Mission on Cancer by improving outcomes in drug-resistant solid tumors.

Topics

Who is involved

OrganisationCityCountryRole
Cardiff UniversityCardiffUnited KingdomCoordinator
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI